CD19 and cancer: Another major challenge for cancer immunotherapies is tumor relapse brought about by pre‐existing heterogeneity or downregulation of target antigens reported in CD19+ B‐cell‐derived malignancies such as acute lymphoblastic leukaemia.158, 159, 160